| 规格: | 98% |
| 分子量: | 304.3 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
Background:
Ticlopidine-d4is intended for use as an internal standard for the quantification of ticlopidine by GC- or LC-MS. Ticlopidine is a thienopyridine P2Y12receptor antagonist.1It inhibits aggregation of human platelets induced by collagen, arachidonic acid , and ADP .2It also inhibits ADP-induced aggregation of rat platelets and decreases thrombus weightin vivoin a rat model of arterio-venous shunt thrombosis when administered at a dose of 100 mg/kg.3Ticlopidine (300 mg/kg) inhibits healing of acetic acid-induced gastric ulcers in rats.4Formulations containing ticlopidine have been used in the prevention of thrombotic stroke.
1.Porto, I., Giubilato, S., De Maria, G.L., et al.Platelet P2Y12 receptor inhibition by thienopyridines: Status and futureExpert Opin. Investig. Drugs18(9)1317-1332(2009) 2.Bruno, J.J.The mechanisms of action of ticlopidineThromb. Res. Suppl.459-67(1983) 3.Sugidachi, A., Asai, F., Ogawa, T., et al.The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBr. J. Pharmacol.129(7)1439-1446(2000) 4.Ma, L., Elliott, S.N., Cirino, G., et al.Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor releaseProc. Nat. Acad. Sci. USA98(11)6470-6475(2001)
m.cnreagent.com